Institute of Agri-Food & Land Use

Senior Lecturer in Molecular Nutrition

Postal Address:
Institute of Agri-Food & Land Use
Queen's University Belfast
David Keir Building
Stranmillis Road
Belfast BT9 5AG

Room:  01.329
Telephone:  +44 (0)28 9097 6541
Fax:  +44 (0)28 9097 6513
Email:  b.green@qub.ac.uk

Administrative Responsibilities

• Deputy Director of Research: Biomolecular Processes Research Cluster
• Degree Board Co-ordinator: BSc (Hons) Food Quality, Safety and Nutrition
• Degree Board Co-ordinator: BSc (Hons) Food Quality, Safety and Nutrition with Professional Studies
• Chair, School Research Ethics Committee
• Module Co-ordinator ALU1002 Food Molecules & Macromolecules
• Module Co-ordinator ALU1004 Human Physiology

Further details on these modules can be obtained by entering the specific code into the Book of Modules

Research Interests

• Discovery of Novel Incretin Hormone Actions
• Nutrient Regulation of gut hormone secretion
• Development of Therapeutic Biomolecules

Professional Qualifications

• BSc (Hons) Biochemistry, Queens University Belfast, 1999.
• PhD Development of DPP IV-resistant analogues of glucagon-like peptide-1 for the treatment of type 2 diabetes, University of Ulster, 2003.
• Chartered Biologist, Institute of Biology, London, 2003.
• Postgraduate Certificate in Higher Education Teaching (PGCHET), Queens University Belfast, 2007.
• Fellow of the Higher Education Academy (HEA)

Indicators of Esteem

• Scientific Advisory Board, Scientia Pharmaceutica
• Editorial Board of  World Journal of Gastroenterology
• Biochemical Society, Member of Theme Panel VII
• Committee member, Institute of Biology - Northern Ireland Branch

Membership of Societies

• Institute of Biology, London (2003-2009)
• Northern Ireland HPSS RRG in Endocrinology, Diabetes and Nutrition (2002-2009)
• Diabetes UK (2002-2009)
• European Association for the Study of Diabetes (EASD) (2002-2009)
• The Biochemical Society (1998-2009)
• Society for Endocrinology (2007)
• The Nutrition Society (2001-2005)
• Irish Endocrine Society (2004)
• European Peptide Society (2004-2009)

Prizes

• July 2009, QUB Teaching Award
• March 2007, Promising Researcher Fellowship (QUB)
• July 2006, Visiting Research Scholarship (RRG in Endocrinology & Diabetes)
• June 2005, Co-author of winning poster at RRG in Endocrinology and Diabetes meeting
• March 2003, 'Best Poster Prize' at RRG in Endocrinology and Diabetes meeting

Reports

Green, B.D. (2004). A week in the city of Hannover: A report on the 2003 EASD Scientists Training Course.  Diabetologia, 47(1): R15-R16.

Green, B.D., McAteer, N., King, K. (2008). Supporting first year student learning in laboratory practicals.  Reflections, 7: 8-9.

Publications

Book Chapters

Green, B.D., Flatt, P.R. (2007). Incretin hormone analogues and mimetics in diabetes therapeutics in "New Therapies for Diabetes".  Best Practice & Research Clinical Endocrinology and Metabolism (Ed) Holly JMP., 21(4): 497-516.

Invited Review Articles

Grieve, D.J., Cassidy, R.S., Green, B.D. (2009). Emerging Cardiovascular Actions of Incretin Hormone Glucagon-Like Peptide-1: Potential therapeutic benefits beyond glycaemic control?  British Journal of Pharmacology, 157: 1340-1351.

Flatt, P.R., Bailey, C.J., Green, B.D. (2009). Recent advances in antidiabetic drug therapies targeting the enteroinsular axis.  Current Drug Metabolism, 10(2): 125-37.

Flatt, P.R., Bailey, C.J., Green, B.D. (2008). Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.  Frontiers in Bioscience, 13(10): 3648-3660.

Green, B.D., Flatt, P.R., Bailey, C.J. (2007). Gliptins: dipeptidyl peptidase-4 (DPP-4) inhibitors to treat type 2 diabetes.  Future Prescriber, 8(3): 7-13.

Green, B.D., Flatt, P.R., Bailey, C.J. (2006). Dipeptidylpeptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of Type 2 Diabetes.  Diabetes and Vascular Disease Research, 3(3): 159-165.

Flatt, P.R., Green, B.D. (2006). Nutrient regulation of pancreatic beta cell function in diabetes - problems and potential solutions.  Biochemical Society Transactions, 34(5): 774-778.

Green, B.D., Flatt, P.R., Bailey, C.J. (2006). Inhibition of dipeptidyl peptidase IV activity as therapy of diabetes.  Expert Opinion on Emerging Drugs, 11(3): 525-539.

Green, B.D., Gault, V.A., O'Harte, F.P.M. Flatt, P.R. (2005). Development and Therapeutic Potential of Incretin Hormone Analogues for Type 2 Diabetes.  The British Journal of Diabetes and Vascular Disease, 5: 134-140.

Green, B.D., Gault, V.A., O'Harte, F.P.M., Flatt, P.R. (2004). Structurally modified analogues of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) as future antidiabetic agents.  Current Pharmaceutical Design, 10(29): 3651-3662.

Peer Reviewed Research Articles

Hand, K.H., Bruen, C., O'Halloran, F., Giblin, L., Green, B.D. (2009). Acute and chronic effects of dietary fatty acids (FAs) on cholecystokinin (CCK) expression, storage and secretion in enteroendocrine STC-1 cells.  Molecular Nutrition and Food Research, (In Press).

Irwin, N., Patterson, S., Flatt, P.R., Green, B.D. (2009). Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.  European Journal of Pharmacology, (In Press).

Green, B.D., Hand, K.V., Dougan, J.E., McDonnell, B., Cassidy, R.S., Grieve, D.J. (2008). GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.  Arch Biochem Biophys, 478: 136-142.

Mallidis, C., Green, B.D., Rogers, D., Agbaje, I.M., Migaud, M., Amigues, E., Hollis, J., McClure, N., Browne, R.A. (2008). Differences In Metabolic Profile In the Testes of Streptozotocin Induced Diabetes Mellitus Mice As Detected By 1H NMR.  International Journal of Andrology, 30: 1-10.

Irwin, N., McClean, P., Cassidy, R.S., O'Harte, F.P.M., Green, B.D., Gault, V.A., Harriott, P., Flatt, P.R. (2007). Comparison of the antidiabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: Studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.  Diabetes/Metabolism Research and Reviews, 23(7): 572-579.

Gault, V.A., Hunter, K., Irwin, N., Greer, B., Green, B.D., Harriott, P., O'Harte, F.P., Flatt, P.R. (2007). Characterisation and glucoregulatory actions of a novel acylated form of the (Pro³)GIP receptor antagonist in type 2 diabetes.  Biological Chemistry, 388(2): 173-179.

Duffy, N.A., Green, B.D., Irwin, N., Gault, V.A., McKillop, A.M., O'Harte, F.P.M., Flatt, P.R. (2007). Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1 (GLP-1).  European Journal of Pharmacology, 568(1-3): 278-286.

O'Harte, F.P.M., Hunter, K., Gault, V.A., Irwin, N., Green, B.D., Greer, B., Harriott, P., Bailey, C.J., Flatt, P.R. (2007). Antagonistic effects of two novel GIP analogues, (Hyp3)GIP and (Hyp3)GIPLys16PAL on the biological actions of GIP and longer term effects in diabetic ob/ob mice.  American Journal of Physiology Endocrinology & Metabolism, 292(6): E1674-1682.

Green, B.D., Irwin, N., Flatt, P.R. (2007). Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice.  Peptides, 28(5): 981-987.

Gault, V.A., Hunter, K., Irwin, N., Green, B.D., Greer, B., Harriott, P., O'Harte, F.P., Flatt, P.R. (2007). Characterisation and biological activity of Glu³ amino acid substituted GIP receptor antagonists.  Arch Biochem Biophys, 461(2): 263-274.

Parker, J.C., Irwin, N., Lavery, K.S., Green, B.D., O'Harte, F.P.M., Gault, V.A., Flatt, P.R. (2007). Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro³)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.  Biological Chemistry, 388(2): 221-226.

Green, B.D., Duffy, N.A., Irwin, N., Gault, V.A., O'Harte, F.P.M., Flatt, P.R. (2006). Inhibition of dipeptidyl peptidase-IV (DPP IV) activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1 (GLP-1).  European Journal of Pharmacology, 547(1-3): 192-199.

Parker, J.C., Lavery, K.S., Irwin, N., Green, B.D., Greer, B., Harriott, P., O'Harte, F.P.M., Gault, V.A., Flatt, P.R. (2006). Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.  Journal of Endocrinology, 191(1): 93-100.

Irwin, N., Clarke, G.C., Green, B.D., Greer, B., Harriott, P., Gault, V.A., O'Harte, F.P.M., Flatt, P.R. (2006). Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.  Biochemical Pharmacology, 72(6): 719-28.

Green, B.D., Irwin, N., Cassidy, R.S., Gault, V.A., Flatt, P.R. (2006). Long-term administration of PACAP receptor antagonist, PACAP(6-27), action impairs glucose tolerance and insulin sensitivity in obese diabetic ob/ob mice.  Peptides, 27(9): 2343-9.

Green, B.D., Kerry, S., Lavery, K., Irwin, N., O'Harte, F.P.M., Harriott, P., Greer, B., Bailey, C.J., Flatt, P.R. (2006). Novel glucagon-like peptide-1 (GLP-1) Analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic ß-cell function after 3-Week daily administration in obese diabetic (ob/ob) mice.  Journal Pharmacology and Experimental Therapeutics, 318(2): 914-21.

Irwin, N., Green, B.D., Parker, J.C., Gault, V.A., O'Harte, F.P.M., Flatt, P.R. (2006). Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro³)GIP(1-16).  Regulatory Peptides, 135(1-2): 45-53.

Liu, H-K., Green, B.D., McClenaghan, N.H., McCluskey, J.T., Flatt, P.R. (2006). Deleterious effects of dehydroepiandrosterone sulphate and dexamethasone on rat insulin-secreting cells under in vitro culture condition.  Bioscience Reports, 26(1): 31-38.

Green, B.D., Irwin, N., Flatt, P.R. (2006). Pituitary adenylate cyclase-activating peptide (PACAP): Assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential.  Peptides, 27(6): 1349-1358.

Irwin, N., O'Harte, F.P.M., Gault, V.A., Mooney, M.H., Green, B.D., Greer, B., Harriott, P., Bailey, C.J., Flatt, P.R. (2006). GIP(LysPAL¹⁶) and GIP(LysPAL³⁷): Novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.  Journal of Medicinal Chemistry, 49(3): 1047-1054.

Irwin, N., Green, B.D., Gault, V.A., Harriott, P., O'Harte, F.P.M., Flatt, P.R. (2006). Stable agonist of Glucose-dependent Insulinotropic Polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not glucose intolerance in aging mice.  Experimental Gerontology, 41(2): 151-156.

Irwin, N., Green, B.D., Gault, V.A., Cassidy, R.S., O'Harte, F.P.M., Harriott, P., Flatt, P.R. (2006). Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice.  Peptides, 27(4): 893-900.

Irwin, N., Green, B.D., Mooney, M.H., Greer, B., Harriott, P., Bailey, C.J., Gault, V.A., O'Harte, F.P.M., Flatt, P.R. (2005). A novel, long-acting agonist of glucose dependent insulinotropic polypeptide (GIP) suitable for once daily administration in type 2 diabetes.  Journal Pharmacology and Experimental Therapeutics, 314(3): 1187-1194.

Gault, V.A., Irwin, N., Green, B.D., McCluskey, J.T., Greer, B., Bailey, C.J., Harriott, P, O'Harte, F.P.M., Flatt, P.R. (2005). Chemical Ablation of Gastric Inhibitory Polypeptide Receptor Action By Daily (Pro³)GIP Administration Improves Glucose Tolerance and Ameliorates Insulin Resistance and Abnormalities of Islet Structure in Obesity-Diabetes.  Diabetes, 54(8): 2436-2446.

Irwin, N., Gault, V.A., Green, B.D., Greer, B, Harriott, P, Bailey, C.J., Flatt, P.R. O'Harte, F.P.M. (2005). Antidiabetic potential of two novel fatty acid derivatized, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).  Biological Chemistry, 386(7): 679-687.

Green, B.D., Gault, V.A., O'Harte, F.P.M., Flatt, PR. (2005). A comparison of the cellular and biological properties of DPP IV-resistant N-glucitol analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).  Diabetes, Obesity and Metabolism, (7): 595-604.

Green, B.D., Liu, H.K., McCluskey, J.T., Duffy, N.A., O'Harte, F.P.M., McClenaghan, N.H., Flatt, P.R. (2005). Function of long-term GLP-1-treated pancreatic beta-cells is improved by preventing DPP IV mediated degradation of GLP-1.  Diabetes, Obesity and Metabolism, (7): 563-569.

Green, B.D., Irwin, N., Gault, V.A., Bailey, C.J., O'Harte, F.P.M., Flatt, P.R. (2005). Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.  Journal of Endocrinology, 185(2): 307-17. 14.

Irwin, N., Green, B.D., Gault, V.A., Greer, B., Harriott, P., Bailey, C.J., Flatt, P.R., O'Harte, F.P.M. (2005). Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.  Journal of Medicinal Chemistry, 48(4): 1244-1250.

Irwin, N., Gault, V.A., Green, B.D., Greer, B., McCluskey, J.T., Harriott, P., O'Harte, F.P.M., Flatt, P.R. (2004). Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.  Biological Chemistry, 385(9): 845-852.

Green, B.D., Gault, V.A., Flatt, P.R., Harriott, P., Greer, B., O'Harte, F.P.M. (2004). Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion and in vivo antidiabetic actions following substitution of Ala8/Ala2 for 2-aminobutyric acid.  Archives of Biochemistry and Biophysics, 428(2): 136-43.

Liu, H-K., Green, B.D., Flatt, P.R., McClenaghan, N.H., McCluskey, J.T. (2004). Effects of long-term exposure to nicotinamide and sodium butyrate on growth, viability and the function of clonal insulin secreting cells.  Endocrine Research, 30(1): 61-8.

Liu, H-K., Green, B.D., McClenaghan, N.H., McCluskey, J.T., Flatt, P.R. (2004). Long-term beneficial effects of vanadate, tungstate and molybdate on insulin secretion and function of cultured beta cells.  Pancreas, 28(4): 364-8.

Green, B.D., Mooney, M.H., Gault, V.A., Bailey, C.J., Irwin, N., Harriott, P., Greer, B., Flatt, P.R., O'Harte, F.P.M. (2004). Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate derivitised native and Ala8-substituted GLP-1 analogues.  Biological Chemistry, 385(2): 169-177.

Green, B.D., Mooney, M.H., Gault, V.A., Bailey, C.J., Irwin, N., Harriott, P., Greer, B., Flatt, P.R., O'Harte, F.P.M. (2004). N-terminal His⁷-modification of GLP-1 generates DPP IV-stable analogues with potent antihyperglycaemic activity.  Journal of Endocrinology, 180(3): 379-388.

Liu, H-K.,Green, B.D., Gault, V.A., McClenaghan, N.H., McCluskey, J.T., Flatt, P.R. (2004). N-acetyl-GLP-1: a DPP IV resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell associated gene expression.  Cell Biology International, 28(1): 69-73.

Green, B.D., Mooney, M.H., Gault, V.A., Irwin, N., Bailey, C.J., Harriott, P., Greer, B., Flatt, P.R., O'Harte, F.P.M. (2004). Lys⁹ for Glu⁹ substitution in glucagon-like peptide-1(7-36)amide (GLP-1) confers DPP IV resistance with cellular and metabolic actions similar to those of established antagonists GLP-1(9-36)amide and exendin (9-39).  Metabolism, 53(2): 252-259.

Green, B.D., Gault, V.A., Mooney, M.H., Irwin, N., Bailey, C.J., Harriott, P., Greer, B., Flatt, P.R., O'Harte, F.P.M. (2003). Novel DPP IV resistant analogues of glucagon-like peptide-1 with potent insulinotropic activity in vitro conferring improved glucose-lowering action in vivo.  Journal of Molecular Endocrinology , 31(3): 529-540.

Green, B.D., Gault, V.A., Irwin, N., Mooney, M.H., Bailey, C.J., Harriott, P., Greer, B., Flatt, P.R. O'Harte, F.P.M. (2003). Metabolic stability, receptor binding, cyclic AMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal (Glu⁹)-substituted analogues of glucagon-like peptide-1.  Biological Chemistry, 384(12): 1543-1551.

Miguel, J.C., Abdel-Wahab, Y.H., Green, B.D., Mathias, P.C., Flatt, P.R. (2003). Cooperative enhancement of insulinotropic action GLP-1 by acetylcholine uncovers paradoxical inhibitory effect of beta cell muscarinic receptor activation on adenylate cyclase activity.  Biochemical Pharmacology, 65(2): 283-292.

Gault, V.A., Green, B.D., Greer, B., Harriott, P., Flatt, P.R., O'Harte, F.P.M. (2003). Effects of the novel (Pro³) GIP antagonist and exendin (9-39) amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.  Diabetologia, 46(2): 222-230.

Conference Papers

Green, B.D., Irwin, N., Flatt, P.R. (2009). Metabolic responses of obestatin peptides in normal and high-fat fed mice.  Amino Acids, 37 (Suppl 1): S9.

Patterson, S., Irwin, N., Green, B.D., Flatt, P.R. (2009). Insulinotropic and glucose lowering effects of small molecule GLP-1-receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.  Diabetologia, 52 (Suppl. 1): pS310.

Hand, K.V., Giblin L, Green, B.D. (2009). Acute and chronic effects of the Omega-3 fatty acid docosahexaenoic acid (DHA) on cholecystokinin (CCK) secretion, storage and metabolism.  Proceedings of the Nutrition Society, (in press).

Green, B.D., Cassidy, R.S., Grieve, D.J. (2009). Exendin-4 attenuates cardiac remodeling in a myocardially infracted mouse model.  Diabetic Medicine, 26(Suppl 1): p15.

Hand, K.H., Rogeau, J., Dougan, J.E., McDonnell, B.M., Green, B.D., Grieve, D.J. (2009). Differential effects of GLP-1 receptor agonists and antagonists on vascular smooth muscle.  Diabetic Medicine, 26(Suppl 1): p16.

Cassidy, R.S., Green, B.D., Grieve, D.J. (2008). The role of glucagon-like peptide-1 in cardiac remodeling after myocardial infarction.  British Society for Cardiovascular Research.

Green, B.D., Irwin, N., Flatt, P.R. (2007). Direct and indirect effects of the anorectic hormone obestatin on glucose regulation and insulin secretion in mice.  Diabetic Medicine, 24(Suppl. 1): p41.

Hand, K.V., Dougan, J.E., Green, B.D., Grieve, D.J. (2007). Vasorelaxant action of Glucagon-like Peptide-1 in rat conductance and resistance arteries.  Scottish Cardiovascular Forum, (poster presentation).

Irwin, N., Clarke, G.C., Gault, V.A., Green, B.D., Harriott, P., O'Harte, F.P.M., Flatt, P.R. (2006). Long-acting analogues of GIP with significantly improved antihyperglycaemic and insulinotropic properties: N-terminal modification versus mid-chain acylation.  Diabetologia, 49(Suppl. 1): p109.

O'Harte, F.P.M., Hunter, K., Gault, V.A., Irwin, N., Harriott, P., Green, B.D., Flatt, P.R. (2006). Cellular and metabolic evaluation of (hydroxyproline3)-GIP as new stable GIP receptor antagonist with antidiabetic potential.  Diabetologia, 49(Suppl. 1): p401.

Flatt, P.R., Irwin, N., McClean, P.L., Green, B.D., Gault, V.A., Bailey, C.J., O'Harte, F.P.M. (2006). Early administration of the GIP receptor antagonist (Pro³)GIP counters development of hyperglycaemia, glucose intolerance and insulin resistance in genetic obesity.  Diabetologia, 49(Suppl. 1): p108.

McKillop, A.M., Duffy, N.A., Lindsay, J.R., Green, B.D., O'Harte, F.P.M., Bell, P.M., Flatt, P.R. (2006). Insulinotropic actions of nateglinide are accompanied by inhibition of dipeptidyl peptidase-IV activity.  Diabetologia, 49(Suppl. 1): p482.

Gault, V.A., Hunter, K., Irwin, N., Green, B.D., O'Harte, F.P.M., Flatt, P.R. (2006). Characterisation of novel glucose-dependent insulinotropic polypeptide (GIP) antagonists generated through amino acid substitution at position Glu3.  Diabetologia, 49(Suppl. 1): p408.

Gault, V.A., Irwin, N., Green, B.D., O'Harte, F.P.M., Flatt, P.R. (2006). Long-acting glucose-dependent insulinotropic polypeptide receptor agonist restores beta-cell responsiveness in ageing mice.  Diabetic Medicine, 23(Suppl. 2): p31 P1.

O'Harte, F.P.M., Irwin, N., Green, B.D., Gault, V.A., Cassidy, R.S., Harriott, P., Flatt, P.R. (2006). Effects of long term activation of glucose-dependent insulinotropic polypeptide receptor on glucose tolerance and insulin secretion in normal mice.  Diabetic Medicine, 23(Suppl. 2): p22 A80.

Irwin, N., Gault, V.A., Green, B.D., Greer, B., Harriott, P., Bailey, C.J., O'Harte, F.P.M., Flatt, P.R. (2006). Novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide (GIP) with enhanced antihyperglycaemic and insulinotropic properties.  Diabetic Medicine, 23(Suppl. 2): p8 A29.

Green, B.D., Liu, H-K,, McClenaghan, N.H., McCluskey, J.T., Flatt, P.R. (2006). Beneficial effects of long-term treatment of pancreatic beta-cells with ultratrace elements vanadate, tungstate and molybdate.  Trace Elements in Medicine, 7(1): p.96.

Lavery, K.S., Green, B.D., Parker, J.C., Irwin, N., Gault, V.A., Flatt, P.R., O'Harte, F.P.M. (2005). The truncated peptide glucagon-like peptide-1(9-36)amide has no insulin releasing activity but retains a significant effect on glucose disposal in vitro and in vivo.  Diabetic Medicine, 22(S2): p17.

O'Harte, F.P.M., Hunter, K., Irwin, N., Green, B.D., Greer, B., Harriott, P., Flatt, P.R. Gault, V.A. (2004). Two novel fatty acid modified GIP analogues with improved antidiabetic potential.  Proceeding of the BioNet Annual Conference, 2(Suppl. 1) p.54.

Lavery, K.S., Parker, J.C., Green, B.D., Irwin, N., Gault, V.A., Flatt, P.R., O'Harte, F.P.M. (2004). The truncated incretin hormone glucagon-like peptide-1(9-36)amide has a significant effect on glucose disposal in vitro and in vivo.  Proceeding of the BioNet Annual Conference, 2(Suppl. 1): p.21

Hunter, K., Irwin, N., Green, B.D., Flatt, P.R., O'Harte, F.P.M., Gault, V.A. (2004). Novel long-acting enzyme-resistant GIP receptor agonists with improved antihyperglycaemic and insulinotropic activity.  Irish Journal of Medical Science, 173(Suppl. 1): p.35-36.

O'Harte, F.P.M., Irwin, N., Gault, V.A., Green, B.D., Flatt, P.R. (2004). C-16 Fatty acid derivatized GIP analogues as potential agents for diabetes therapy.  Irish Journal of Medical Science, 173(Suppl. 1): p.10.

O'Harte, F.P.M., Irwin, N., Gault, V.A., Green, B.D., Flatt, P.R. (2004). Novel fatty acid derived Assessment of the antidiabetic potential of two fatty acid derivatized GIP analogues.  Proceedings of the 15th International Symposium on Regulatory peptides, 122: 33-34.

Gault, V.A., Irwin, N., O'Harte, F.P.M., Green, B.D., Flatt, P.R. (2004). Antidiabetic potential of a long-acting derivative of GIP following once daily administration in type 2 diabetes.  Proceedings of the 15th International Symposium on Regulatory peptides, 122: 20.

McCluskey, J.T., Irwin, I., Gault, V.A., Green, B.D., Flatt, P.R., O'Harte, F.P.M. (2004). Longer-term ablation of GIP signalling in normal mice demonstrates importance of GIP for glucose homeostatis as part of the enteroinsular axis.  In: Proceedings of the EASD Study Group Meeting on Molecular Aspects of Pancreatic Islet Function, Prien Germany, p. 26.

Irwin, N., Gault, V.A., Green, B.D., Harriott, P., O'Harte, F.P.M., Flatt, P.R. (2004). Long-acting Tyr1-modified analogues of GIP with significantly improved antihyperglycaemic and insulinotropic properties.  Diabetologia, 47(Suppl. 1): P109.

Flatt, P.R., Irwin, N., Green, B.D., Harriott, P., Gault, V.A., O'Harte, F.P.M. (2004). Daily administration of GIP receptor antagonist alleviates glucose intolerance and counters insulin resistance in an animal model of obesity and type 2 diabetes.  Diabetologia, 47(Suppl. 1): P781.

Green, B.D., Irwin, N., Gault, V.A., O'Harte, F.P.M., Bailey, C.J., Flatt, P.R. (2004). Chronic treatment of obese hyperglycaemic ob/ob mice with exendin(9-39)amide suggests a minor role for endogenous GLP-1 in metabolic abnormalities of obesity-diabetes.  Diabetologia, 47(Suppl. 1): P659.

O'Harte, F.P.M., Green, B.D., Gault, V.A., Irwin, N., Mooney, M.H., Harriott, P., Greer, B., Flatt, P.R. (2004). (Lys⁹)GLP-1 lacks insulinotropic activity but acts as a potent novel GLP-1 receptor antagonist in vivo.  Diabetic Medicine, 21(Suppl. 2): P26.

Gault, V.A., Green, B.D., Irwin, N., Harriott, P., Greer, B., Flatt, P.R., O'Harte, F.P.M. (2004). Development and characterisation of novel N-terminal Glu⁹-substituted agonists of glucagon-like peptide-1 (GLP-1).  Diabetic Medicine, 21(Suppl. 2): A93.

Green, B.D., Gault, V.A., Mooney, M.H., Irwin, N., Harriott, P., Greer, B., O'Harte, F.P.M. Flatt, P.R. (2004). Molecular, cellular and biological characteristics of DPP IV-resistant acetylated analogues of GLP-1.  Diabetic Medicine, 21(Suppl. 2): A94.

McCluskey, J.T., Liu, H-K,, Green, B.D., McClenaghan, N.H., Flatt, P.R. (2003). The beneficial effects on insulin secretion and function of beta cells following long-term culture with ultratrace elements: vanadate, tungstate and molybdate.  Irish Journal of Medical Science, 172(Suppl. 1): p40.

Irwin, I., Green, B.D., Liu, H-K,, McCluskey, J.T., McClenaghan, N.H., Gault, V.A., Harriott, P., Greer, B., O'Harte, F.P.M., Flatt, P.R. (2003). DPP IV resistant GLP-1 analogue N-acetyl-GLP-1 has improved effects on pancreatic beta-cell associated gene expression.  Irish Journal of Medical Science, 172(Suppl. 1): p24.

O'Harte, F.P.M., Green, B.D., Mooney, M.H., Gault, V.A., Irwin, N., Harriott, P., Greer, B., Flatt, P.R. (2003). (Lys⁹)GLP-1 possesses DPP IV resistance and cellular and metabolic actions similar to those of established antagonists GLP-1(9-36)amide and exendin(9-39).  Irish Journal of Medical Science, 172(Suppl. 1): p10.

Green, B.D., Irwin, N., Gault, V.A., Mooney, M.H., Harriott, P., Greer, B., O'Harte, F.P.M., Flatt, P.R. (2003). DPP IV degradation, receptor binding, insulin secreting and antihyperglycaemic characteristics of palmitate-dervitised GLP-1 analogues.  Irish Journal of Medical Science, 172(Suppl. 1): p41.

Green, B.D., Gault, V.A., O'Harte, F.P.M., Greer, B., Harriott, P., Flatt, P.R. (2003). Stability, cAMP production, insulin secretion and antihyperglycaemic activity of Pro³- substituted analogues of GLP-1 and GIP.  Diabetic Medicine, 20(Suppl. 2): P10.

O'Harte, F.P.M., Gault, V.A., Harriott, P., Green, B.D., Flatt, P.R. (2002). Comparative studies with exendin(9-39)amide and the novel (Pro³)GIP receptor antagonist indicates that glucose-dependent insulinotropic polypeptide is the major hormone of the enteroinsular axis.  Diabetologia, 45(Suppl. 2): A178.

Gault, V.A., Green, B.D., Greer, B., Harriott, P., Flatt, P.R., O'Harte, F.P.M. (2002). N-terminally modified analogues of glucose dependent insulinotropic polypeptide exhibit improved insulinotropic activity and antihyperglycaemic potential compared with glucagon-like peptide-1 counterparts.  Diabetologia, 45(Suppl. 2): A177.

Green, B.D., O'Harte, F.P.M., Greer, B., Harriott, P., Flatt, P.R. (2002). Enhanced plasma stability, receptor binding, cyclic AMP production and insulin-releasing activity of two novel penultimate N-terminally substituted analogues of glucagon-like peptide-1.  Diabetologia, 45(Suppl. 2): A159.

Green, B.D., Flatt, P.R., Harriott, P., O'Harte, F.P.M. (2002). Novel stable Val8 glucagon-like peptide-1 analogue with potent insulin releasing activity.  Diabetic Medicine, 19(Suppl. 1): 80.

O'Harte, F.P.M., Green, B.D., Greer, B., Harriott, P., Flatt, P.R. (2002). N-acetyl glucagon-like peptide-1 is resistant to dipeptidyl-peptidase IV and exhibits strong insulinotropic activity.  Diabetic Medicine, 19(Suppl. 1): 14.

Green, B.D., O'Harte, F.P.M., Harriott, P., Greer, B., Flatt, P.R. (2001). N-terminally modified GLP-1(7-36)amide is resistant to dipeptidyl peptidase-IV degradation whilst maintaining insulinotropic action.  Proceedings of the Nutrition Society, 60: 154A.

PhD Student Supervision

Kerry Lavery; The role and therapeutic potential of GLP-1 analogues as a target for type 2 diabetes (2003-2006)

Eamon Rafferty; Endocrine and nutrient mechanisms involved in the stimulation of GLP-1 secretion. (2006-2009)

Katharine Hand; Screening of milk bioactives that stimulate release of gut satiety signals. (2007-2010)

Andrew Agnew; Investigating the biological actions of obestatin peptides. (2008-2011)

Sheila McCartan; The effect of fish oils on the activation and subsequent interactions of monocytes and endothelial cells (co-supervised with Dr L Powell, 2008-2011).

 Get Adobe Reader to view and print PDF files.